exosome based therapies Search Results


exosome nanoparticles  (Exosome Diagnostics)
86
Exosome Diagnostics exosome nanoparticles
The schematic illustration of Lipid <t>nanoparticles</t> ( A ) Preparation process of LNM nanoparticles. ( B ) Transmission electron microscopy (TEM) image of LNM nanoparticles. ( C ) Mn 2 ⁺ content in MC38 cells at different time periods. ( D ) Expression of P-STING protein under the action of different concentrations of LNM. ( E ) Expression of P-IRF3 protein under the action of different concentrations of LNM. ( F ) Tumor volume in mice. ( G ) Tumor weight in mice. ( H ) Statistical analysis of CD8 T cell positive rate in mouse splenocytes. ( I ) Statistical analysis of CD4 T cell positive rate in mouse splenocytes. ( J ) Expression of IFN-γ in mouse serum. ( K ) Expression of IL-6 in mouse serum.(ns, no significance; *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).
Exosome Nanoparticles, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exosome nanoparticles/product/Exosome Diagnostics
Average 86 stars, based on 1 article reviews
exosome nanoparticles - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
exosome based mirna therapy  (Exosome Diagnostics)
86
Exosome Diagnostics exosome based mirna therapy
The schematic illustration of Lipid <t>nanoparticles</t> ( A ) Preparation process of LNM nanoparticles. ( B ) Transmission electron microscopy (TEM) image of LNM nanoparticles. ( C ) Mn 2 ⁺ content in MC38 cells at different time periods. ( D ) Expression of P-STING protein under the action of different concentrations of LNM. ( E ) Expression of P-IRF3 protein under the action of different concentrations of LNM. ( F ) Tumor volume in mice. ( G ) Tumor weight in mice. ( H ) Statistical analysis of CD8 T cell positive rate in mouse splenocytes. ( I ) Statistical analysis of CD4 T cell positive rate in mouse splenocytes. ( J ) Expression of IFN-γ in mouse serum. ( K ) Expression of IL-6 in mouse serum.(ns, no significance; *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).
Exosome Based Mirna Therapy, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exosome based mirna therapy/product/Exosome Diagnostics
Average 86 stars, based on 1 article reviews
exosome based mirna therapy - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
exosome based therapy 400 exosomes  (Exosome Diagnostics)
86
Exosome Diagnostics exosome based therapy 400 exosomes
The schematic illustration of Lipid <t>nanoparticles</t> ( A ) Preparation process of LNM nanoparticles. ( B ) Transmission electron microscopy (TEM) image of LNM nanoparticles. ( C ) Mn 2 ⁺ content in MC38 cells at different time periods. ( D ) Expression of P-STING protein under the action of different concentrations of LNM. ( E ) Expression of P-IRF3 protein under the action of different concentrations of LNM. ( F ) Tumor volume in mice. ( G ) Tumor weight in mice. ( H ) Statistical analysis of CD8 T cell positive rate in mouse splenocytes. ( I ) Statistical analysis of CD4 T cell positive rate in mouse splenocytes. ( J ) Expression of IFN-γ in mouse serum. ( K ) Expression of IL-6 in mouse serum.(ns, no significance; *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).
Exosome Based Therapy 400 Exosomes, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/exosome based therapy 400 exosomes/product/Exosome Diagnostics
Average 86 stars, based on 1 article reviews
exosome based therapy 400 exosomes - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


The schematic illustration of Lipid nanoparticles ( A ) Preparation process of LNM nanoparticles. ( B ) Transmission electron microscopy (TEM) image of LNM nanoparticles. ( C ) Mn 2 ⁺ content in MC38 cells at different time periods. ( D ) Expression of P-STING protein under the action of different concentrations of LNM. ( E ) Expression of P-IRF3 protein under the action of different concentrations of LNM. ( F ) Tumor volume in mice. ( G ) Tumor weight in mice. ( H ) Statistical analysis of CD8 T cell positive rate in mouse splenocytes. ( I ) Statistical analysis of CD4 T cell positive rate in mouse splenocytes. ( J ) Expression of IFN-γ in mouse serum. ( K ) Expression of IL-6 in mouse serum.(ns, no significance; *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: The schematic illustration of Lipid nanoparticles ( A ) Preparation process of LNM nanoparticles. ( B ) Transmission electron microscopy (TEM) image of LNM nanoparticles. ( C ) Mn 2 ⁺ content in MC38 cells at different time periods. ( D ) Expression of P-STING protein under the action of different concentrations of LNM. ( E ) Expression of P-IRF3 protein under the action of different concentrations of LNM. ( F ) Tumor volume in mice. ( G ) Tumor weight in mice. ( H ) Statistical analysis of CD8 T cell positive rate in mouse splenocytes. ( I ) Statistical analysis of CD4 T cell positive rate in mouse splenocytes. ( J ) Expression of IFN-γ in mouse serum. ( K ) Expression of IL-6 in mouse serum.(ns, no significance; *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Transmission Assay, Electron Microscopy, Expressing

( A ) Schematic diagram of polymer nanoparticle synthesis. ( B ) TEM images of polymeric nanoparticles at pH 7.0 and pH 5.0. ( C ) pH-responsive cGAMP release kinetics of polymeric nanoparticles. ( D ) Nanoparticles promoted the ability of cGAMP to induce murine IFN‐β (mIFN‐β) in DC2.4 cells. ( E ) Nanoparticles outperformed controls to induce mIFN‐β) in DC2.4 cells. ( F ) The dose‐dependent cGAMP‐selective IFN response.( G ) The superior INF induction ability of nanoparticles than controls. ( H) Tumor volume in mice. ( I and J ) Representative flow cytometry plots ( I ) and quantification ( J ). ( K) Tumor weight in mice.( ns, no significance;*p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: ( A ) Schematic diagram of polymer nanoparticle synthesis. ( B ) TEM images of polymeric nanoparticles at pH 7.0 and pH 5.0. ( C ) pH-responsive cGAMP release kinetics of polymeric nanoparticles. ( D ) Nanoparticles promoted the ability of cGAMP to induce murine IFN‐β (mIFN‐β) in DC2.4 cells. ( E ) Nanoparticles outperformed controls to induce mIFN‐β) in DC2.4 cells. ( F ) The dose‐dependent cGAMP‐selective IFN response.( G ) The superior INF induction ability of nanoparticles than controls. ( H) Tumor volume in mice. ( I and J ) Representative flow cytometry plots ( I ) and quantification ( J ). ( K) Tumor weight in mice.( ns, no significance;*p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Polymer, Flow Cytometry

The schematic illustration of metal nanoparticles ( A ) Preparation process of metal nanoparticles. ( B ) Representative images of MDA-MB-231 cell clone formation under different treatments. ( C and D ) Representative images ( C ) and quantification ( D ) of DC maturation (CD80, CD86 of CD45 BMDCs) induced by supernatant from Zn 2 ⁺-treated cancer cells. ( E ) Zn 2 ⁺ concentration in mouse tumor tissue. ( F ) Tumor volume in mice. ( G) Photographs of tumors excised from mice. ( H ) Tumor weight in mice.( *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: The schematic illustration of metal nanoparticles ( A ) Preparation process of metal nanoparticles. ( B ) Representative images of MDA-MB-231 cell clone formation under different treatments. ( C and D ) Representative images ( C ) and quantification ( D ) of DC maturation (CD80, CD86 of CD45 BMDCs) induced by supernatant from Zn 2 ⁺-treated cancer cells. ( E ) Zn 2 ⁺ concentration in mouse tumor tissue. ( F ) Tumor volume in mice. ( G) Photographs of tumors excised from mice. ( H ) Tumor weight in mice.( *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Concentration Assay

The schematic illustration of Mesoporous silica nanoparticles (MSNs) ( A ) Schematic diagram of mesoporous silica nanoparticle preparation. ( B ) Representative TEM images of mesoporous silica nanoparticles incubated for 12 and 72 h under different conditions. ( C ) Flow cytometry of 4T1 cell apoptosis after different treatments. ( D ) Flow cytometry analysis of mature DC cells after incubation with 4T1 cells subjected to different treatments. ( E ) Whole-animal in vivo bioluminescence images of 4T1 luciferase-expressing mice after different treatments. ( F ) Mesoporous silica nanoparticles increased the expression of IFN-β, IL-6, IFN-γ, and TNF-α in vivo. ( G ) Tumor volume change curves in mice under different treatments. ( **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: The schematic illustration of Mesoporous silica nanoparticles (MSNs) ( A ) Schematic diagram of mesoporous silica nanoparticle preparation. ( B ) Representative TEM images of mesoporous silica nanoparticles incubated for 12 and 72 h under different conditions. ( C ) Flow cytometry of 4T1 cell apoptosis after different treatments. ( D ) Flow cytometry analysis of mature DC cells after incubation with 4T1 cells subjected to different treatments. ( E ) Whole-animal in vivo bioluminescence images of 4T1 luciferase-expressing mice after different treatments. ( F ) Mesoporous silica nanoparticles increased the expression of IFN-β, IL-6, IFN-γ, and TNF-α in vivo. ( G ) Tumor volume change curves in mice under different treatments. ( **p < 0.01,***p < 0.001, ****p < 0.0001 ).

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Incubation, Flow Cytometry, In Vivo, Luciferase, Expressing

The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Expressing

Potential of STING nanoparticles in combination therapy with radiotherapy. ( A and B ) TEM images of STING nanoparticles. ( C ) Image of cancer cell survival obtained by incubating with different concentrations of STING nanoparticles for 24 hours, then irradiating with different doses of X-rays. ( D ) Representative images of colony cluster staining after receiving various treatments. ( E ) Survival rate of cancer cells in different treatment groups. ( F )Viability of cancer cells after treatment with different treatment groups. ( G ) Tumor weight in mice. ( H ) Image of tumors collected from mice after treatment with various drugs. ( **p < 0.01,***p < 0.001, ****p < 0.0001 ). , , ,

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: Potential of STING nanoparticles in combination therapy with radiotherapy. ( A and B ) TEM images of STING nanoparticles. ( C ) Image of cancer cell survival obtained by incubating with different concentrations of STING nanoparticles for 24 hours, then irradiating with different doses of X-rays. ( D ) Representative images of colony cluster staining after receiving various treatments. ( E ) Survival rate of cancer cells in different treatment groups. ( F )Viability of cancer cells after treatment with different treatment groups. ( G ) Tumor weight in mice. ( H ) Image of tumors collected from mice after treatment with various drugs. ( **p < 0.01,***p < 0.001, ****p < 0.0001 ). , , ,

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Staining

Potential of STING nanoparticles in combination therapy with phototherapy. ( A ) Schematic diagram of STING nanoparticle synthesis and its TEM image. ( B ) Flow cytometry analysis of apoptosis levels in cancer cells after different treatments. ( C ) Infrared thermal images of tumor models after different treatments. ( D) Photographic images of mouse tumors. ( E ) Relative tumor growth curves of various treatment groups. ( F ) Temperature profiles of PTA tumor models. , ,

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: Potential of STING nanoparticles in combination therapy with phototherapy. ( A ) Schematic diagram of STING nanoparticle synthesis and its TEM image. ( B ) Flow cytometry analysis of apoptosis levels in cancer cells after different treatments. ( C ) Infrared thermal images of tumor models after different treatments. ( D) Photographic images of mouse tumors. ( E ) Relative tumor growth curves of various treatment groups. ( F ) Temperature profiles of PTA tumor models. , ,

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: Flow Cytometry

Potential of STING nanoparticles in combination therapy with other immunotherapies. ( A ) SEM image of STING nanoparticles. ( B and C ) Release of HMGB1 and ATP from LLC cells after different treatments, indicating the effect of STING nanoparticles in achieving ICD. ( D ) Cytokine levels of TNF-α (i), and IFN-β (ii) in DCs after treatments with different formulations. ( E ) Representative corresponding quantification of CRT release in cells after different treatments. ( F–K ) Tumor pictures, average tumor growth curves, and survival curves of CT26 tumor-bearing mice after treatment with STING nanoparticles. (** p < 0.01,**** p < 0.0001). ,

Journal: International Journal of Nanomedicine

Article Title: The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy

doi: 10.2147/IJN.S598118

Figure Lengend Snippet: Potential of STING nanoparticles in combination therapy with other immunotherapies. ( A ) SEM image of STING nanoparticles. ( B and C ) Release of HMGB1 and ATP from LLC cells after different treatments, indicating the effect of STING nanoparticles in achieving ICD. ( D ) Cytokine levels of TNF-α (i), and IFN-β (ii) in DCs after treatments with different formulations. ( E ) Representative corresponding quantification of CRT release in cells after different treatments. ( F–K ) Tumor pictures, average tumor growth curves, and survival curves of CT26 tumor-bearing mice after treatment with STING nanoparticles. (** p < 0.01,**** p < 0.0001). ,

Article Snippet: The schematic illustration of Exosome nanoparticles ( A ) Preparation of exosome nanoparticles. ( B ) TEM images of exosome nanoparticles at pH 7.4 and pH 5.5. ( C) Expression of cGAS-STING pathway-related proteins in 4T1 cells after different treatments. ( D–F) Release of CRT (D), HMGB1 ( E ), and ATP ( F ) from 4T1 cell supernatant after different treatments. ( G ) 4T1 Tumor growth curves of 4T1 tumor-bearing mice with various treatments. ( H–J ) Representative FCM ( H ) and quantification analysis ( I and J ) of CTLs in tumor. ( ns, no significance;***p < 0.001, ****p < 0.0001) .

Techniques: